Serum microRNAs in clear cell carcinoma of the ovary

Taiwanese Journal of Obstetrics and Gynecology

Volumn 53, Issue 4, 2014, Pages 536-541

  Chao, Angel ^a,b   Lai, Chyong Huey ^a,b   Chen, Hua Chien ^c,d   Lin, Chiao Yun ^a,b   Tsai, Chia Lung ^a,b   Tang, Yun Hsin ^a,b   Huang, Huei Jean ^a,b   Lin, Chen Tao ^a,b   Chen, Min Yu ^a,b   Huang, Kuang Gen ^a,b   Chou, Hung Hsueh ^a,b   Chang, Ting Chang ^a,b   Chen, Shu Jen ^c,d   Wang, Tzu Hao ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Clear cell carcinoma; Hsa miR 130a; MicroRNA; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CEL MICRORNA 238; HSA MICRORNA 125B; HSA MICRORNA 130A; HSA MICRORNA 138; HSA MICRORNA 181A; HSA MICRORNA 187; HSA MICRORNA 195; HSA MICRORNA 196A; HSA MICRORNA 202; HSA MICRORNA 25; HSA MICRORNA 29B 1; HSA MICRORNA 363; HSA MICRORNA 365; HSA MICRORNA 519D; HSA MICRORNA 565; HSA MICRORNA 760; MICRORNA; MICRORNA 1; MICRORNA 200B; MICRORNA 29B; UNCLASSIFIED DRUG; MIRN130 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CAENORHABDITIS ELEGANS; CANCER GROWTH; CANCER RECURRENCE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENDOMETRIOSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE IDENTIFICATION; GENE ISOLATION; GENETIC SCREENING; HUMAN; MESENTERY; OVARY CARCINOMA; PERITONEUM METASTASIS; REAL TIME POLYMERASE CHAIN REACTION; REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION; ADENOCARCINOMA; BLOOD; DISEASE COURSE; EVALUATION STUDY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA, CLEAR CELL; ADULT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84916198427     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2014.07.005     Document Type: Article

References (52)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012, 460:237-249.
3. Lim D., Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology 2013, 45:229-242.
4. Penson R.T., Dizon D.S., Birrer M.J. Clear cell cancer of the ovary. Curr Opin Oncol 2013, 25:553-557.
5. Cancer Registry Annual Report, 2008 Taiwan 2010, Department of Health, Executive Yuan. http://tcr.cph.ntu.edu.tw/main.php?Page=N1.
6. Ushijima K. Current status of gynecologic cancer in Japan. JGynecol Oncol 2009, 20:67-71.
7. del Carmen M.G., Birrer M., Schorge J.O. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol 2012, 126:481-490.
8. Wiegand K.C., Shah S.P., Al-Agha O.M., Zhao Y., Tse K., Zeng T., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. NEngl J Med 2010, 363:1532-1543.
9. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
10. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
11. Calin G.A., Liu C.G., Sevignani C., Ferracin M., Felli N., Dumitru C.D., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004, 101:11755-11760.
12. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
13. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
14. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68:425-433.
15. Chao A., Lin C.Y., Lee Y.S., Tsai C.L., Wei P.C., Hsueh S., et al. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 2012, 31:764-775.
16. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
17. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
18. Lodes M.J., Caraballo M., Suciu D., Munro S., Kumar A., Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009, 4:e6229.
19. Huang X., Liang M., Dittmar R., Wang L. Extracellular microRNAs in urologic malignancies: chances and challenges. Int J Mol Sci 2013, 14:14785-14799.
20. Chen H.C., Chen G.H., Chen Y.H., Liao W.L., Liu C.Y., Chang K.P., et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009, 100:1002-1011.
21. Huang Y., Chen H.C., Chiang C.W., Yeh C.T., Chen S.J., Chou C.K. Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells. Nucleic Acids Res 2012, 40:10478-10493.
22. Koberle V., Kronenberger B., Pleli T., Trojan J., Imelmann E., Peveling-Oberhag J., et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013, 49:3442-3449.
23. Tanaka K., Miyata H., Yamasaki M., Sugimura K., Takahashi T., Kurokawa Y., et al. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 2013, 20(Suppl.3):S607-S615.
24. Yang I.P., Tsai H.L., Huang C.W., Huang M.Y., Hou M.F., Juo S.H., et al. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One 2013, 8:e66842.
25. Heegaard N.H., Schetter A.J., Welsh J.A., Yoneda M., Bowman E.D., Harris C.C. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012, 130:1378-1386.
26. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., Hoon D.S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011, 57:84-91.
27. Morimura R., Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Nagata H., et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011, 105:1733-1740.
28. Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010, 102:1174-1179.
29. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008, 110:13-21.
30. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112:55-59.
31. Kan C.W., Hahn M.A., Gard G.B., Maidens J., Huh J.Y., Marsh D.J., et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 2012, 12:627.
32. Chung Y.W., Bae H.S., Song J.Y., Lee J.K., Lee N.W., Kim T., et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Int J Gynecol Cancer 2013, 23:673-679.
33. Guo F., Tian J., Lin Y., Jin Y., Wang L., Cui M. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. JInt Med Res 2013, 41(5):1456-1461.
34. Duffy M.J., Bonfrer J.M., Kulpa J., Rustin G.J., Soletormos G., Torre G.C., et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005, 15:679-691.
35. Jacobs I., Bast R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989, 4:1-12.
36. Chao A., Lee L.Y., Hsueh C., Lin C.Y., Tsai C.L., Chao A.S., et al. Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels. Taiwan J Obstet Gynecol 2013, 52:185-191.
37. Ness R.B. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003, 189:280-294.
38. Pearce C.L., Templeman C., Rossing M.A., Lee A., Near A.M., Webb P.M., et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012, 13:385-394.
39. Jia S.Z., Yang Y., Lang J., Sun P., Leng J. Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis. Hum Reprod 2013, 28:322-330.
40. Wang W.T., Zhao Y.N., Han B.W., Hong S.J., Chen Y.Q. Circulating microRNAs identified in a genome-wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis. JClin Endocrinol Metab 2013, 98:281-289.
41. Suryawanshi S., Vlad A.M., Lin H.M., Mantia-Smaldone G., Laskey R., Lee M., et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2013, 19:1213-1224.
42. Hager M., Pedersen C.C., Larsen M.T., Andersen M.K., Hother C., Gronbaek K., et al. MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF-beta1 stimulation in granulocytic precursors. Blood 2011, 118:6649-6659.
43. Xu N., Shen C., Luo Y., Xia L., Xue F., Xia Q., et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 2012, 425:468-472.
44. Kovaleva V., Mora R., Park Y.J., Plass C., Chiramel A.I., Bartenschlager R., et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res 2012, 72:1763-1772.
45. Yang L., Li N., Wang H., Jia X., Wang X., Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 2012, 28:592-600.
46. Acunzo M., Visone R., Romano G., Veronese A., Lovat F., Palmieri D., et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2012, 31:634-642.
47. Kubiczkova L., Kryukov F., Slaby O., Dementyeva E., Jarkovsky J., Nekvindova J., et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014, 99:511-518.
48. Zhou J., Zheng Q., Xu T., Liao D., Zhang Y., Yang S., et al. Associations between physical activity-related miRNAs and metabolic syndrome. Horm Metab Res 2014, 46:201-205.
49. Wang T.H., Chao A. Microarray analysis of gene expression of cancer to guide the use of chemotherapeutics. Taiwan J Obstet Gynecol 2007, 46:222-229.
50. Chao A., Wang T.H., Lai C.H. Overview of microarray analysis of gene expression and its applications to cervical cancer investigation. Taiwan J Obstet Gynecol 2007, 46:363-373.
51. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012, 5:492-497.
52. Duttagupta R., Jiang R., Gollub J., Getts R.C., Jones K.W. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011, 6:e20769.